Search

Displaying results 2531 - 2540 of 9667 in total
  1. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    [L23524] In November 2021, the same indication was approved by the EMA. … Imdevimab is a monoclonal antibody combined with [casirivimab] in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19.

  2. Drug

    Norethynodrel

    go.drugbank.com/drugs/DB09371
    Approved

    It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with MESTRANOL.

  3. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218026, A218031] By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids such as [morphine] at a comparable or decreased risk of opioid-related adverse … [A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor

  4. Drug

    CX-046684

    go.drugbank.com/drugs/DB19414
    Approved

    It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.[L40074]

  5. Drug

    Sarracenia Purpurea

    go.drugbank.com/drugs/DB13965
    ApprovedWithdrawn

    It was used as an injectable pain reliever and during the 19th century, _Sarracenia purpurea_ was used as a treatment of smallpox [A32509]. … It is widely distributed across North America and has been used as a traditional medicinal herb in many aboriginal communities [A32509, A32510].

  6. Drug

    Pentazocine

    go.drugbank.com/drugs/DB00652
    ApprovedVet approved

    It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)

    Products: Talwin - Liq 30mg/ml
  7. Drug

    Carisoprodol

    go.drugbank.com/drugs/DB00395
    Approved

    In January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential

  8. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin. … Viomycin was derived from the actinomycete _Streptomyces puniceus_.

  9. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected

  10. Drug

    L-Acetylleucine

    go.drugbank.com/drugs/DB16956
    ApprovedInvestigational

    DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine